Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib in advanced hepatocellular carcinoma
NCT06478927Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jan 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of palbociclib in hepatocellular carcinoma (HCC), sponsored by Henan Cancer Hospital. Primary endpoint: Progression-Free Survival at 2 years. Started Jan 2024; status: recruiting.
02
Drugs
palbociclib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06478927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06478927.